A review of how the brain's orexin and serotonin systems interact to regulate food intake, spontaneous physical activity (like fidgeting), and energy expenditure — with implications for obesity treatment.
Spontaneous activity burns caloriesThe orexin-serotonin brain circuit controls unconscious movements like fidgeting and standing — a largely untapped target for obesity treatment
What the researchers found
The review identifies a specific orexin-serotonin axis running from the lateral hypothalamus to the dorsal raphe nucleus that co-regulates three key components of energy balance: food intake, spontaneous physical activity (SPA), and energy expenditure.
Orexin neurons in the lateral hypothalamus project to serotonin-producing neurons in the dorsal raphe nucleus, which then influence cortical and subcortical regions controlling movement, feeding, and calorie burning. The review also discusses how impaired serotonin function in animal obesity models, genetic variants in the serotonin system, and serotonin-targeting drugs (including SSRIs and uptake inhibitors) all affect obesity risk and treatment.
Why it matters
Most obesity research focuses on diet and intentional exercise, but spontaneous physical activity — all the small movements you do without thinking — actually burns significant calories. This review highlights that the brain has dedicated circuits controlling this 'NEAT' (non-exercise activity thermogenesis), and that the orexin-serotonin connection could be a druggable target. Understanding this axis could lead to entirely new approaches to obesity that work by increasing unconscious calorie burning rather than suppressing appetite.
How the study worked
This is a comprehensive narrative review synthesizing evidence from animal lesion and stimulation studies, neuroanatomical tracing studies, pharmacological experiments, genetic association studies, and clinical observations on serotonin-related drugs and obesity.
What this study cannot tell us
As a narrative review, no new data is presented. Much of the evidence for the orexin-serotonin axis comes from rodent studies, and translating brain circuit manipulations to safe human therapeutics remains challenging. The review does not systematically assess study quality. The concept of pharmacologically boosting spontaneous activity remains largely theoretical.
How to read the evidence
This is a narrative review of primarily preclinical evidence. It provides an excellent mechanistic framework but most supporting data comes from animal models. No clinical trials of orexin-serotonin-targeted obesity treatments are discussed.
When this study was published
Published in 2022 in WIREs Mechanisms of Disease. The review captures relatively recent understanding of the orexin-serotonin interaction in energy balance.
The bigger picture
While GLP-1 drugs like semaglutide dominate obesity treatment by reducing appetite, the orexin-serotonin axis represents a fundamentally different approach — increasing energy expenditure through spontaneous movement rather than restricting intake. This review connects neuropeptide biology with the practical observation that lean people tend to fidget more and sit less. As the obesity treatment landscape evolves, energy expenditure pathways may complement appetite suppression strategies.
Questions still open
- Could drugs targeting the orexin-serotonin axis safely increase spontaneous physical activity in obese humans?
- How does the orexin-serotonin energy balance system interact with GLP-1 signaling?
- Do SSRIs and other serotonin-modulating psychiatric drugs contribute to weight gain by disrupting this axis?
Common questions
What is spontaneous physical activity and why does it matter for weight?
What is orexin and how does it relate to obesity?
Read the original research
Orexin, serotonin, and energy balance.
WIREs mechanisms of disease, 14(1), e1536
Citation
Mavanji, Vijayakumar; Pomonis, Brianna; Kotz, Catherine M. (2022). Orexin, serotonin, and energy balance.. WIREs mechanisms of disease, 14(1), e1536. https://doi.org/10.1002/wsbm.1536